Publicacións (47) Publicacións de JOSÉ PABLO MIRAMONTES GONZÁLEZ

2023

  1. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

    Precision Cancer Medicine

  2. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  3. Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID-19 pneumonia: An open-label randomised trial

    European Journal of Clinical Investigation, Vol. 53, Núm. 1

  4. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  5. Estimands: a new way of interpreting the results of clinical essays

    Spanish Journal of Medicine, Vol. 3, Núm. 1

  6. Reply to «Considerations to the manuscript cancer and elderly: Two incompatible concepts for intensive care?»

    Revista Espanola de Geriatria y Gerontologia

2022

  1. Cancer and elderly: Two incompatible concepts for intensive care?

    Revista Espanola de Geriatria y Gerontologia

  2. Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic

    Journal of Clinical Medicine, Vol. 11, Núm. 12

  3. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  4. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  2. Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection

    Journal of Personalized Medicine, Vol. 11, Núm. 7

  3. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  4. Predictive modeling of poor outcome in severe covid-19: A single-center observational study based on clinical, cytokine and laboratory profiles

    Journal of Clinical Medicine, Vol. 10, Núm. 22

  5. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  6. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18

2020

  1. Author Correction: A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function (Scientific Reports, (2019), 9, 1, (5055), 10.1038/s41598-019-41504-7)

    Scientific Reports

  2. VAV3 rs7528153 and VAV3-AS1 rs1185222 polymorphisms are associated with an increased risk of developing hypertension

    European Journal of Internal Medicine, Vol. 80, pp. 60-65

2019

  1. A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function

    Scientific Reports, Vol. 9, Núm. 1

  2. Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis

    Diabetes Research and Clinical Practice, Vol. 148, pp. 10-13